Regulatory News
Monday, June 6, 2016
BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
* Announced on Sunday Phase 3 trial results of CABOMETYX
(cabozantinib) tablets demonstrating significant overall
survival benefit for previously treated patients with advanced
renal cell carcinoma...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment